Acurx Pharmaceuticals, Inc. (ACXP) vs Sonoma Pharmaceuticals, Inc. (SNOA)

A side-by-side comparison of Acurx Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ACXP vs SNOA

growth of $100 · dividends reinvested · last 5y
ACXP -99.2% (-61.6%/yr)SNOA -99.2% (-62.0%/yr)ACXP compounded faster over this window
020406080100Start $10020222023202420252026$1$1
ACXP SNOA

ACXP vs SNOA: by the numbers

  • •SNOA is the larger company ($6M vs $6M market cap).
  • •Both run net losses; ACXP's is the smaller (0.00% vs -10.33% net margin).

Metrics side by side

Valuation

MetricACXPSNOA
P/S ratioN/A0.26
P/B ratio0.690.88

Profitability

MetricACXPSNOA
Gross margin0.00%38.91%
Operating margin0.00%-6.41%
Net margin0.00%-10.33%
ROE-92.08%-34.33%
ROIC-94.08%-10.98%

Growth (annualized)

MetricACXPSNOA
Revenue CAGR (5Y)N/A5.79%
Total return CAGR (5Y)-57.41%-59.29%

Frequently asked

How have ACXP and SNOA total returns compared?
Over the past 5 years, ACXP delivered -57.41% and SNOA delivered -59.29% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.